A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

This study is testing a drug called canakinumab (which targets inflammation in the body) in patients with low-risk myelodysplastic syndrome (MDS) — a bone marrow disorder where the marrow doesn't produce enough healthy blood cells — or a related pre-cancerous blood condition called CCUS. The goal is to see if reducing inflammation can improve blood cell production. **You may be eligible if...** - You are 18 or older - You have a diagnosis of low or intermediate-risk MDS (per standard classification), OR - You have a condition called CCUS (clonal cytopenia of undetermined significance) with a confirmed genetic mutation and persistent low blood counts - For some groups: your MDS has not responded to prior treatments such as erythropoiesis-stimulating agents or hypomethylating agents - You have symptomatic anemia or need blood transfusions **You may NOT be eligible if...** - You have high-risk MDS or acute leukemia - You have active, serious infections - You are pregnant or breastfeeding - You have serious organ dysfunction - You have had a prior stem cell transplant (in some cohorts) Talk to your doctor to see if this trial is right for you.